951 results match your criteria Seminars in Cutaneous Medicine and Surgery [Journal]


ALIGN PsA: Advancing a Multidisciplinary Approach in PsA.

Semin Cutan Med Surg 2018 Dec;37(6S):S125-S134

Franchellie M. Cadwell Associate Professor of Medicine Weill Medical College of Cornell University The Hospital for Special Surgery New York Presbyterian Hospital New York, NY.

Psoriasis is a chronic skin condition that is associated with several comorbidities and co-manifestations that reduce patient quality of life. Psoriatic arthritis (PsA) is a form of spondyloarthritis that is associated with psoriasis and typically involves peripheral disease, axial disease, enthesitis, dactylitis, and skin and nail lesions. Psoriatic arthritis is associated with a substantial psychosocial and functional burden and can lead to irreversible joint damage if left untreated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.057DOI Listing
December 2018
6 Reads

Melasma: update on management.

Semin Cutan Med Surg 2018 Dec;37(4):217-225

Dermatology and Laser Surgery Center, Houston, Texas, USA.

Melasma is a common, acquired, chronic cutaneous pigment disorder that is often difficult to treat and has a high recurrence rate. The goal of a melasma treatment regimen is to decrease pigment production and increase elimination. Topical tyrosinase inhibitors block melanin synthesis and thereby reduce pigment production. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/buy_now/?id=796
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.049DOI Listing
December 2018
21 Reads

Vaginal rejuvenation: whose turf?

Semin Cutan Med Surg 2018 Dec;37(4):236-237

Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Many medical conditions can cross over the territories of various specialties. These conditions may benefit from, or even require, a multidisciplinary approach. While ideally this leads to a collaborative and coveted patient-centered care model, it can also give rise to competitive turf wars. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.059DOI Listing
December 2018
6 Reads

The vaginal wellness consultation for treatment with energy-based devices.

Authors:
Misha D Miller

Semin Cutan Med Surg 2018 Dec;37(4):233-235

Mohs Micrographic Surgery and Cutaneous Oncology, Department of Dermatology, University of Colorado, Denver, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.054DOI Listing
December 2018
1 Read

Vaginal wellness: whose turf is it?

Semin Cutan Med Surg 2018 Dec;37(4):238-241

The Skin and Laser Treatment Institute, Walnut Creek, California, USA.

Dermatologists were the pioneers in the development of laser technology and have the most experience using these lasers to treat the external genitalia for many cutaneous disorders. Dermatologists who have experience and expertise using lasers and devices, are already using them to treat the external genitalia, and are comfortable performing female gynecologic exams may want to explore the wide range of options that are available to treat the functional and aesthetic needs of the female population. Dermatologists should work with obstetricians and gynecologists to ensure that patients are proper candidates for the procedures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.060DOI Listing
December 2018
2 Reads

Aesthetic Consideration in Women's Health, Introduction.

Semin Cutan Med Surg 2018 Dec;37(4):209

Westchester Dermatology and Mohs Surgery, White Plains Hospital Physician Associates, Mount Kisco and Scarsdale, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.058DOI Listing
December 2018
1 Read

Updates on the understanding and treatment of cellulite.

Semin Cutan Med Surg 2018 Dec;37(4):242-246

SkinCare Physicians, Inc., Chestnut Hill, Massachusetts, USA.

Cellulite is a common dermatologic condition and frequent cause of cosmetic concern among women. This paper aims to update what is known about the pathogenesis of cellulite and reviews targeted treatment modalities that address its underlying components of microvascular dysfunction, endocrine-mediated inflammation, and connective tissue fibrosclerosis. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/buy_now/?id=801
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.056DOI Listing
December 2018
6 Reads

Aesthetic considerations in female skin of color: what you need to know.

Semin Cutan Med Surg 2018 Dec;37(4):210-216

Department of Dermatology, Weill Cornell Medical College, New York, New York, USA.

The world is flat when it comes to aesthetic treatments, meaning women and men from all walks of life, regardless of culture and ethnicity or even socioeconomic status, are seeking ways to improve their appearance, prevent aging, and rejuvenate their skin. Year after year, statistics show a steady increase in people of color undergoing aesthetic treatments, with neurotoxins, fillers, laser resurfacing, and body contouring being the most sought-after procedures. When treating this cohort of patients, however, dermatologists need to be sensitized to how a patient's ethnicity affects facial structure, the tissue reaction to treatments, and patient's specific expectations for recommended therapies. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/buy_now/?id=795
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.053DOI Listing
December 2018
22 Reads

Treatment of female pattern hair loss with combination therapy.

Semin Cutan Med Surg 2018 Dec;37(4):247-253

Department of Dermatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Female pattern hair loss (FPHL) is a common nonscarring alopecia characterized by progressive loss of terminal hairs. FPHL is a major concern for women and has a high impact on quality of life. Therapeutic regimen is often challenging and requires multiple combinations of topical, systemic, and interventional therapies to control hair loss and produce satisfactory hair regrowth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.043DOI Listing
December 2018
2 Reads

Common allergens present in personal care products: identification, diagnosis, and management.

Semin Cutan Med Surg 2018 Dec;37(4):254-262

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.

The incidence of allergic contact dermatitis (ACD) reactions to personal care products has progressively increased, affecting women more so than men. Fragrances and preservatives are the major sensitizers behind cosmetic-induced ACD, due to their ubiquitous presence in these products, though emulsifiers, ultraviolet filters, and botanical allergens have been implicated as well. While patch testing is the standard for diagnosing ACD, many cosmetic-specific antigens are not currently included within the commercially available kits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.029DOI Listing
December 2018
7 Reads

Device-based treatment for vaginal wellness.

Semin Cutan Med Surg 2018 Dec;37(4):226-232

Yale University School of Medicine, New Haven, Connecticut, USA.

Genitourinary syndrome of menopause (GSM), encompassing the disorders of atrophic vaginitis, urinary incontinence, and pelvic prolapse, affects the majority of postmenopausal women, as well as patients who are undergoing breast cancer treatement, post-ovarectomy, post-radiation, and breast-feeding. There is a need for better treatment options for these common conditions that adversely affect physical function and quality of life and that are often underserved by existing options. Lasers have been used to treat genitourinary tissue for over 40 years, and over the past decade, several lasers and radiofrequency devices have been developed and clinically tested for the treatment of GSM, with an accumulating body of evidence demonstrating their safety and efficacy. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/buy_now/?id=797
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.052DOI Listing
December 2018
17 Reads

JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.

Semin Cutan Med Surg 2018 09;37(3):198-208

Tufts University School of Medicine; Boston, Massachusetts, USA.

Cutaneous inflammatory conditions such as psoriasis, atopic dermatitis, alopecia areata, vitiligo, and connective tissue diseases often remain a challenge to treat. Although there is an in-depth understanding of the clinical presentation of these diseases, much less is known regarding the pathophysiology. This has limited the effective treatment options for patients. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/buy_now/?id=793
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.041DOI Listing
September 2018
5 Reads

Novel therapies in the treatment of atopic dermatitis.

Semin Cutan Med Surg 2018 Sep;37(3):190-197

Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Atopic dermatitis (AD) is a common cutaneous condition characterized by epidermal barrier disruption, severe skin inflammation, and pruritus. As a result of our growing understanding of disease pathogenesis, the therapeutic armamentarium to manage AD is rapidly expanding. Moving beyond broadly immunosuppressive agents, newer therapies for AD offer more targeted immunomodulation in the forms of phosphodiesterase 4 inhibitors, Janus kinase inhibitors, and anticytokine monoclonal antibodies. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/buy_now/?id=792
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.044DOI Listing
September 2018
5 Reads

Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.

Semin Cutan Med Surg 2018 09;37(3):182-189

Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.

Hidradenitis suppurativa (HS) is a frequently devastating inflammatory skin disorder. Although many treatments have been tried and tested to date, there is only one Food and Drug Administration-approved treatment option, adalimumab, which is currently indicated for moderateto- severe HS. Our understanding of the management of HS with biologic agents and with nonantibiotic and/ or antimicrobial systemic therapies continues to evolve. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/buy_now/?id=791
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.042DOI Listing
September 2018
20 Reads

Targeted therapies for psoriatic arthritis: an update for the dermatologist.

Semin Cutan Med Surg 2018 Sep;37(3):173-181

Departments of Dermatology and Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Dermatologists are on the front line to identify psoriatic arthritis (PsA) in their patients with psoriasis. PsA is a prevalent and underdiagnosed disease with potential long-term complications and sequelae for patients. Targeted biologics have transformed the landscape of psoriasis and PsA therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.045DOI Listing
September 2018
4 Reads

Targeted therapies for pediatric psoriasis.

Semin Cutan Med Surg 2018 Sep;37(3):167-172

Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Children who are recalcitrant to topical therapy for their moderate to severe plaque psoriasis and/or highly visible lesions may be candidates for systemic therapy. Methotrexate has been the most commonly used systemic agent in children. However, at least 25% of patients are now treated with biologics, especially tumor necrosis factor-α inhibitors, and their use is expanding as their availability, demonstrated safety and efficacy, and practitioner experience are increasing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.048DOI Listing
September 2018
1 Read

Oral small molecules for psoriasis.

Semin Cutan Med Surg 2018 Sep;37(3):163-166

Keck School of Medicine of USC, University of Southern California, Los Angeles, California, USA.

Psoriasis is chronic inflammatory skin condition that imposes a significant physical and psychosocial burden on patients. Moderate to severe psoriasis often requires systemic treatments, including oral systemic therapies and biologics. An addition to the treatment repository for psoriasis is oral small molecules, which include apremilast, tofacitinib, and ponesimod. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.046DOI Listing
September 2018
2 Reads
2.402 Impact Factor

IL-23 inhibitors for moderate-to-severe psoriasis.

Semin Cutan Med Surg 2018 Sep;37(3):158-162

Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit. At this time, 2 inhibitors of IL-23 p19 have been approved by the United States Food and Drug Administration, guselkumab and tildrakizumab. Two other agents, risankizumab and mirikizumab, have completed phase 3 and phase 2 of development, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.047DOI Listing
September 2018
14 Reads

IL-17 inhibitors for psoriasis.

Semin Cutan Med Surg 2018 Sep;37(3):148-157

Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA.

The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.051DOI Listing
September 2018
19 Reads

Ustekinumab for the treatment of psoriasis: an evidence update.

Semin Cutan Med Surg 2018 Sep;37(3):143-147

Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom.

Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/buy_now/?id=785
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.040DOI Listing
September 2018
13 Reads

TNF inhibitors for psoriasis.

Semin Cutan Med Surg 2018 Sep;37(3):134-142

Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine, New York, New York, USA.

Tumor necrosis factor (TNF)-α has been identified as a key cytokine mediating cutaneous inflammation in the pathogenesis of psoriasis. The TNF inhibitors (TNFi's) infliximab, adalimumab, and etanercept are efficacious, Food and Drug Administration-approved medications for the treatment of moderate-to-severe plaque psoriasis. Each drug has a unique pharmacological profile that can have therapeutic implications when choosing a particular TNFi for a patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.039DOI Listing
September 2018
3 Reads

Using targeted therapies for inflammatory dermatoses.

Authors:
Jeffrey M Sobell

Semin Cutan Med Surg 2018 09;37(3):133

Psoriasis Treatment Center, Skincare Physicians, Chestnut Hill, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.050DOI Listing
September 2018
1 Read

Treating Acne in Patients With Skin of Color.

Semin Cutan Med Surg 2018 Jun;37(3S):S71-S73

Adjunct Professor Schulich School of Medicine and Dentistry Western University Windsor, Ontario, Canada.

Patients with skin of color are more likely to develop acne and postinflammatory hyperpigmentation (PIH). Many therapies for acne have demonstrated efficacy in darker skin types and in the treatment of PIH. Semin Cutan Med Surg 37(supp3):S71-S73 © 2018 published by Frontline Medical Communications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.027DOI Listing
June 2018
1 Read

Treating Acne in Adult Women.

Semin Cutan Med Surg 2018 Jun;37(3S):S67-S70

Adjunct Professor Schulich School of Medicine and Dentistry Western University Windsor, Ontario, Canada.

Acne can persist into adulthood or erupt de novo at any point after adolescence. Adult acne is more common in women than in men. Considerations for treating acne in adult women include childbearing potential, pregnancy, lactation, and concomitant skin conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.026DOI Listing
June 2018
1 Read

Advances in Acne and Rosacea Therapy.

Semin Cutan Med Surg 2018 Jun;37(3S):S63-S66

Adjunct Professor Schulich School of Medicine and Dentistry Western University Windsor, Ontario, Canada.

New topical therapies have demonstrated efficacy in patients with moderate or severe acne who might otherwise have required therapy with systemic antibiotics or isotretinoin. Increasing knowledge about the pathogenesis of acne has facilitated the development of therapies with novel modes of action. New and investigational therapies also are available or in development for the treatment of both the papulopustular and erythematous manifestations of rosacea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.025DOI Listing
June 2018
6 Reads

Current Concepts in Acne Pathogenesis: Pathways to Inflammation.

Semin Cutan Med Surg 2018 Jun;37(3S):S60-S62

Clinical Associate Professor of Dermatology University of Alabama at Birmingham Dermatology and Skin Care Center of Birmingham Birmingham, Alabama.

Acne is a disease of pilosebaceous inflammation. Pivotal in pathogenesis are the roles of hormones (insulin, insulin-like growth factor-1, androgens), Propionibacterium acnes, lipogenesis, and a proinflammatory lipid profile. Innate immune responses are induced through interaction with toll-like receptors and inflammasome activation initially and subsequently through adaptive immune activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.024DOI Listing
June 2018
1 Read

Introduction.

Semin Cutan Med Surg 2018 Jun;37(3S):S59

Chair Director of Dermatology Clinical Research Division Head of Dermatology Henry Ford Hospital Detroit, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.023DOI Listing
June 2018
1 Read

Immunotherapy for melanoma.

Semin Cutan Med Surg 2018 Jun;37(2):127-131

University of California, San Francisco, California, USA.

Immunotherapy for the treatment of advanced melanoma has become a primary treatment in the clinic. Current therapies include systemic cytokines, immune checkpoint inhibitors, and localized intratumoral therapies. Checkpoint inhibitors block natural pathways that dampen or inhibit an immune response to stimulus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.028DOI Listing
June 2018
7 Reads

Biomarkers for immune therapy in melanoma.

Semin Cutan Med Surg 2018 Jun;37(2):120-126

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA.

Immune checkpoint inhibitors have dramatically transformed melanoma treatment options. However, intrinsic and acquired resistance remain fundamental limitations to extending the benefits to all patients. Understanding molecular and clinical features that correlate with response to treatment (biomarkers) may unravel therapeutic resistance, assist in treatment decision-making, and facilitate drug development. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/abstract/biomarkers-for-immu
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.019DOI Listing
June 2018
5 Reads
2.402 Impact Factor

The role of targeted therapy for melanoma in the immunotherapy era.

Authors:
Ryan J Sullivan

Semin Cutan Med Surg 2018 Jun;37(2):112-119

Center for Melanoma, MGH Cancer Center, Boston, Massachusetts, USA.

Over the past 10 years of remarkable development of both molecularly targeted and immune-targeted therapy for the treatment of melanoma, a clear preference of immunotherapy over molecularly targeted therapy has emerged among melanoma treatment providers. Still, the clinical data remain remarkable for patients with BRAF-mutant stage III and IV melanoma, and there seems to be a clear benefit of BRAF-targeted therapy for these patients. The key, then, is to identify the best way to use BRAF-targeted therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.021DOI Listing
June 2018
1 Read

Adjuvant therapy for resected high-risk melanoma.

Semin Cutan Med Surg 2018 Jun;37(2):109-111

Cutaneous Oncology Program, Moffitt Cancer Center, Tampa, Florida, USA.

Melanoma is an aggressive cancer that arises from melanocytes that can both locally invade surrounding tissues as well as metastasize systemically. If detected early, melanoma can be curable with surgical resection. However, despite complete removal, high-risk resected melanomas have a significant rate of both local and distant recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.022DOI Listing
June 2018
3 Reads

Surgical management of melanoma.

Semin Cutan Med Surg 2018 Jun;37(2):101-108

Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.

Surgery remains one of the key treatment modalities for melanoma. Wide excision of the primary site with sentinel lymph node biopsy for selected patients has been recognized as the standard surgical approach for patients with early-stage disease. Controversies persist regarding margin width, indications for sentinel lymph node biopsy, and surgical management of regional nodal basins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.018DOI Listing
June 2018
3 Reads

Pathologic analysis of melanocytic neoplasms.

Semin Cutan Med Surg 2018 Jun;37(2):88-100

Department of Dermatology and Cutaneous Surgery, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.

Recent advances in techniques for pathologic evaluation of melanocytic neoplasms, updates in staging, and novel treatment and prognostic assays have brought pathologists to the forefront of the care of the melanoma patient. Specimen procurement, handling, and evaluation are all key to the production of a pathology report that guides the clinician to the proper treatment of the patient. Recent, relevant changes in the pathologic analysis of melanocytic neoplasms, highlighting the AJCC 8th edition guidelines, and pathologic changes related to therapy are discussed herein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2017.054DOI Listing
June 2018
1 Read

Melanocytic Neoplasms, Introduction.

Authors:
Adil I Daud

Semin Cutan Med Surg 2018 Jun;37(2):87

University of California, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.028DOI Listing
June 2018
1 Read

Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology Seminar.

Semin Cutan Med Surg 2018 Jun;37(4S):S75-S84

Clinical Associate Professor Department of Dermatology University of California, Irvine School of Medicine Private Practice Santa Barbara, CA.

Updates on managing some of the most common dermatologic conditions for which patients seek care illuminated presentations at the Skin Disease Education Foundation's 42nd Annual Hawaii Dermatology Seminar®. This educational supplement summarizes the highlights of clinical sessions presented during this CME/CE conference. Treatment of psoriasis has continued to advance, with three interleukin (IL)-17 antagonists approved by the US Food and Drug Administration (FDA) and a fourth in phase 3 trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.031DOI Listing
June 2018
17 Reads

Molecular advances in cutaneous T-cell lymphoma.

Semin Cutan Med Surg 2018 Mar;37(1):81-86

Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.

Cutaneous T-cell lymphoma (CTCL) is a group of malignancies derived from skin-homing T cells. Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common CTCL variants. In recent years, the genetic landscape of SS/MF has been characterized using genome-wide nextgeneration sequencing approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.007DOI Listing
March 2018
4 Reads

Maximizing the clinical utility of descriptive lymphoid pathology reporting.

Semin Cutan Med Surg 2018 Mar;37(1):75-80

Pathology and Dermatology, UCSF Dermatopathology and Oral Pathology Service, University of California, San Francisco, San Francisco, California, USA.

Dermatopathology reporting can be both exact and inexact. Exact reporting represents the use of terminology that corresponds to a disease sui generis, such as discoid lupus erythematosus or disseminated superficial porokeratosis. Inexact reporting can vary greatly amongst various practitioners-both in terms of the exact semantics used and also stylistically-and can be used habitually by pathologists as a means to provide cover for diagnostic uncertainty or inexperience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.016DOI Listing
March 2018
5 Reads

Approach to dermal-based lymphoid infiltrates and proliferations.

Semin Cutan Med Surg 2018 Mar;37(1):61-74

Department of Pathology, The American British Cowdray Medical Center, Mexico City, Mexico.

The histopathological diagnosis of dermal-based lymphoid infiltrates and proliferations is often challenging due to the vast list of biologically diverse entities that archetypally or occasionally center in the mid-dermis, especially because significant overlap exists in their clinical, histopathologic, and immunophenotypic features. The differential diagnosis includes reactive infiltrates in common and rare inflammatory dermatoses, benign conditions that may mimic lymphoid neoplasms (pseudolymphomas), and true clonal proliferations arising either primarily in the skin or rarely in extracutaneous tissues with secondary cutaneous dissemination. While numerous histopathological and immunophenotypic features have been reported to support a definitive diagnosis, no single ancillary test is sufficient for their distinction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.015DOI Listing
March 2018
1 Read

Histopathologic approach to epidermotropic lymphocytic infiltrates.

Semin Cutan Med Surg 2018 Mar;37(1):56-60

Palo Alto Medical Foundation, Palo Alto, California, USA.

Mycosis fungoides is the most common and therefore quintessential cutaneous lymphoma and is typically characterized by an epidermotropic infiltrate of atypical monoclonal CD4+ lymphocytes. Classical histopathologic findings include epidermotropism, lymphocytes with convoluted nuclear contours and surrounding perinuclear "halos," and papillary dermal fibrosis. Atypical lymphocytes may occasionally form Pautrier's microabscesses with tagging of lymphocytes along the basal keratinocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.003DOI Listing
March 2018
1 Read

Primary cutaneous B-cell lymphomas- clinical and histopathologic features, differential diagnosis, and treatment.

Semin Cutan Med Surg 2018 Mar;37(1):49-55

Harvard Medical School, Boston, Massachusetts, USA.

Cutaneous B-cell lymphomas (CBCLs) are a heterogeneous group of diseases that can have variable presentations, prognoses, and treatments. The proper identification of a CBCL hinges on proper histopathologic and clinical evaluation. Comprising 25% to 30% of the primary cutaneous lymphomas, incident cases of CBCL are rare. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/issues/view/cutaneous-lymphoma-1/?pg
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.014DOI Listing
March 2018
7 Reads

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder-clinical and histopathologic features, differential diagnosis, and treatment.

Semin Cutan Med Surg 2018 Mar;37(1):39-48

Department of Pathology & Dermatology, Division of Dermatopathology, University of Virginia, Charlottesville, Virginia, USA.

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder usually presents as a slow-growing and asymptomatic solitary lesion in the form of a nodule or tumor in the head and neck region. By definition, it is histologically characterized by small- to medium-sized CD4+ lymphocytes involving the dermis in a dense and either nodular or diffuse pattern. Epidermotropism should be absent or minimal. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/issues/view/cutaneous-lymphoma-1/?pg
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.006DOI Listing
March 2018
7 Reads

NK/T-cell lymphoma, nasal type, γδ T-cell lymphoma, and CD8-positive epidermotropic T-cell lymphoma-clinical and histopathologic features, differential diagnosis, and treatment.

Semin Cutan Med Surg 2018 03;37(1):30-38

Dermatopathology Division, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

The cytotoxic lymphomas of the skin constitute a heterogeneous group of rare lymphoproliferative diseases that are derived from mature T cells and natural killer (NK) cells that express cytotoxic molecules (T-cell intracellular antigen- 1, granzyme A/B, and perforin). Although frequently characterized by an aggressive course and poor prognosis, these diseases can have variable clinical behavior. This review delivers up-to-date information about the clinical presentation, histopathologic features, differential diagnosis, and therapy of extranodal NK/T-cell lymphoma, nasal type, primary cutaneous gamma delta T-cell lymphoma, and primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331058PMC
March 2018
31 Reads

Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.

Semin Cutan Med Surg 2018 Mar;37(1):24-29

Department of Dermatology, University Medical Center, Göttingen, Germany.

Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPD) are the second most common form of cutaneous T-cell lymphoma. CD30+ LPD include lymphomatoid papulosis, primary cutaneous anaplastic large-cell lymphoma, and borderline lesions. Despite expression of CD30 by the neoplastic cells as the hallmark of these disorders, they differ in their clinical presentation and histological features as well as the course, the prognosis, and consecutively in the treatment. Read More

View Article

Download full-text PDF

Source
https://scmsjournal.com/issues/view/cutaneous-lymphoma-1/?pg
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.001DOI Listing
March 2018
4 Reads

Sézary syndrome-clinical and histopathologic features, differential diagnosis, and treatment.

Semin Cutan Med Surg 2018 Mar;37(1):18-23

Department of Dermatology, University of Cincinnati, Cincinnati, Ohio, USA.

Sézary syndrome (SS) is a rare subtype of cutaneous T-cell lymphoma marked by erythroderma, circulating neoplastic T cells, and poor prognosis. Its low incidence has made the study of its etiology, immunologic/molecular pathways, and effective treatments difficult. Because histopathology may be nonspecific in SS, microscopic findings must be correlated with the clinical presentation and the results of blood evaluation in order to make the diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.005DOI Listing
March 2018
3 Reads

Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment.

Authors:
Rein Willemze

Semin Cutan Med Surg 2018 Mar;37(1):11-17

Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.

Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, which typically presents with erythematous patches and plaques, histopathologically characterized by superficial infiltrates of small to mediumsized atypical epidermotropic T cells. Apart from this classic type of MF, many clinical and/or histopathologic variants have been described. Correct diagnosis of these MF variants is important, but may be difficult, because they may mimic a wide variety of inflammatory skin diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.004DOI Listing
March 2018
1 Read

Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.

Authors:
Lorenzo Cerroni

Semin Cutan Med Surg 2018 Mar;37(1):2-10

Research Unit Dermatopathology, Medical University of Graz, Graz, Austria.

Mycosis fungoides (MF) is the most common type of cutaneous lymphoma. The term MF should be used only for the classical presentation of the disease characterized by the evolution of patches, plaques, and tumors or for variants showing a similar clinical course. MF is divided into 3 clinical phases: patch, plaque, and tumor stage, and the clinical course is usually protracted over years or decades. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.002DOI Listing
March 2018
2 Reads

Introduction.

Semin Cutan Med Surg 2017 Dec;36(4S):S91

Professor of Dermatology and Pediatrics Vice Chair, Department of Dermatology Chief, Pediatric and Adolescent Dermatology University of California San Diego School of Medicine and Rady Children's Hospital-San Diego University of California San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2017.047DOI Listing
December 2017
3 Reads

Practical Strategies for Optimizing Management of Psoriasis.

Semin Cutan Med Surg 2018 Feb;37(2S):S52-S55

Chairman, Division of Dermatology Baylor University Medical Center Dallas, Texas.

Approximately 30% of patients with moderate plaque psoriasis and 20% of those with severe psoriasis have inadequate disease control with their current therapeutic regimens. Among the factors that affect treatment efficacy are drug selection and lack of patient adherence to treatment, which is often due to patient frustration that psoriasis is a chronic, multisystemic, and incurable disease. By forming a strong therapeutic alliance with patients and by asking them about their expectations for treatment, clinicians have a better chance of providing patients with more effective and durable relief from their psoriasis symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.012DOI Listing
February 2018
9 Reads

Common and Not-So-Common Comorbidities of Psoriasis.

Semin Cutan Med Surg 2018 Feb;37(2S):S48-S51

Director of Dermatology Research Department of Dermatology Kaiser Permanente Los Angeles Medical Center Los Angeles, California.

Plaque psoriasis is increasingly recognized as a multisystemic disease whose most common comorbidities include psoriatic arthritis, cardiovascular disease, metabolic syndrome, overweight/obesity, inflammatory bowel disease, and depression. The presence of such comorbidities affects the therapeutic choices for clinicians. Patients often visit dermatologists more frequently than they do other clinicians, so it is incumbent upon dermatologists to recognize and address early signs of psoriatic comorbidities to prevent further deterioration and improve their patients' quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.011DOI Listing
February 2018
9 Reads